Niki BioSolutions (NIKI) director discloses 1,832 directly owned shares on Form 3

Rhea-AI Filing Summary

Niki BioSolutions, Inc. director Justin Che Yuen Wu filed an initial statement of beneficial ownership. The filing reports 1,832 shares of Common Stock held with direct ownership as of 2026-07-20. The entry records holdings only, without any reported purchase or sale transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Wu Justin Che Yuen

Role Director

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,832 shares (Direct)

Key Figures

Common Stock holdings: 1,832 shares

1 metrics

Common Stock holdings 1,832 shares Directly owned by director Justin Che Yuen Wu as reported on 2026-07-20

FAQ

What does Niki BioSolutions (NIKI) report in this Form 3 filing?

The Form 3 reports that director Justin Che Yuen Wu beneficially owns 1,832 shares of Niki BioSolutions Common Stock with direct ownership. It is an initial ownership statement and does not disclose any buy or sell transactions.

How many Niki BioSolutions (NIKI) shares does Justin Che Yuen Wu hold?

Justin Che Yuen Wu is reported to hold 1,832 shares of Niki BioSolutions, Inc. Common Stock. These shares are listed as directly owned and represent his beneficial ownership position reported in this initial Form 3 filing.

Does the Niki BioSolutions (NIKI) Form 3 show any recent insider trades?

No. The Form 3 for Niki BioSolutions, Inc. lists 1,832 directly owned shares for director Justin Che Yuen Wu but does not report any purchase or sale transactions. It functions solely as an initial ownership disclosure.

What type of security is reported in Niki BioSolutions (NIKI) director’s Form 3?

The filing reports ownership of Common Stock of Niki BioSolutions, Inc., totaling 1,832 shares held directly by director Justin Che Yuen Wu. No derivative securities or options positions are included in this Form 3 data.

Is Justin Che Yuen Wu a 10% owner of Niki BioSolutions (NIKI) according to the Form 3?

According to the Form 3, Justin Che Yuen Wu is reported as a director of Niki BioSolutions, Inc. and not as a 10% owner. His disclosed holding is 1,832 shares of Common Stock with direct ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 08/13/2026 - 09:56 AM Accepted by SEC EDGAR 08/13/2026 - 09:55 AM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Wu Justin Che Yuen

(Last) (First) (Middle)

C/O NIKI BIOSOLUTIONS, INC.

116 VILLAGE BOULEVARD, SUITE 200

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/20/2026

3. Issuer Name and Ticker or Trading Symbol
Niki BioSolutions, Inc. [ NIKI ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1,832	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Justin Wu	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)